ReCode Therapeutics

ReCode Therapeutics is a technology company.

Active

Updated: Feb 17, 2026 ·

Recent News & Mentions

Sep 1, 2023FundingReCode Therapeutics - Series B Oct 1, 2021FundingReCode Therapeutics - Series B Mar 1, 2020FundingReCode Therapeutics - Series A

Financial History

ReCode Therapeutics has raised $210.0M across 3 funding rounds. Most recently, it raised $50.0M Series B in September 2023.

Total Raised

$210.0M

Valuation

N/A

Funding Rounds Raised

Date	Round	Other Investors
Sep 1, 2023	$50.0M Series B	Bioluminescence Ventures, InterWest, Intuitive Ventures, MPM Capital, OrbiMed, Pfizer Venture Investments, Polaris Partners, Vida Ventures, Sam Altman
Oct 1, 2021	$80.0M Series B	Bioluminescence Ventures, InterWest, MPM Capital, OrbiMed, Pfizer Venture Investments, Polaris Partners, Vida Ventures, Sam Altman
Mar 1, 2020	$80.0M Series A	Bioluminescence Ventures, InterWest, MPM Capital, OrbiMed, Pfizer Venture Investments, Vida Ventures, Sam Altman

Financial History

ReCode Therapeutics has raised $210.0M across 3 funding rounds.

Total Raised

$210.0M

Valuation

N/A

Deep Dive

High-Level Overview

ReCode Therapeutics is a clinical-stage genetic medicines company developing mRNA and gene correction therapeutics for rare genetic diseases like cystic fibrosis (CF) and primary ciliary dyskinesia (PCD), targeting patient populations with limited or no existing treatments.[1][2][3] It serves patients with genetically defined diseases by addressing root causes through its proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP) platform, which enables precise delivery to organs beyond the liver, such as lungs, via routes like inhalation or intravenous administration.[1][3][6] The company solves the key limitation of prior LNP systems—liver confinement—unlocking broader genetic medicine applications, with lead candidates RCT1100 (DNAI1 modulator for PCD, Phase 1) and RCT2100 (CFTR modulator for CF, Phase 1, recently entering Phase 2 combo trial with ivacaftor as of Nov 2025).[2][4][5] Growth momentum includes recognition as a Fierce 15 biotech in 2022 and pipeline expansion into musculoskeletal, CNS, liver, and infectious diseases.[2][3][4]

Origin Story

Founded in 2015 and headquartered in Dallas, TX, ReCode emerged from unconventional thinking in LNP delivery by co-founder Daniel J. Siegwart, Ph.D., a University of Texas professor who pioneered SORT technology by adding a fifth distinct lipid to conventional LNPs, enabling organ-specific targeting beyond the liver.[2][3][5] Co-founder Philip Thomas complements the team, with CEO Shehnaaz Suliman, M.D., MBA, M.Phil. leading since early stages.[2][5] The idea stemmed from decades of LNP limitations observed in mRNA advances like COVID-19 vaccines; Siegwart's breakthrough, published in scientific literature, directly birthed the SORT platform, fueling early traction through a pipeline focused on CF and PCD—diseases with high unmet need.[1][3] Pivotal moments include 2022 Fierce 15 honors and recent 2025 clinical advancements, humanizing the mission to realize genetic medicines' full promise for rare disease patients.[2]

Core Differentiators

ReCode stands out in genetic medicines through its SORT LNP platform, a modular, first-in-class system transforming delivery paradigms:

Precision Targeting: Fifth lipid enables selective delivery to lungs, spleen, and other organs, bypassing liver uptake inherent in first-generation LNPs used in mRNA vaccines.[1][3][6]
Versatile Cargo and Modalities: Packages diverse payloads like mRNA, siRNA, gene editors, tRNA, and ASOs (e.g., 6 mRNA, 1 transformer base editor in pipeline), with redosing capability and mixed cargo potential.[1][4][6]
Administration Flexibility: Supports inhaled, IV, subcutaneous, intramuscular, and intrathecal routes for optimal biodistribution to disease-relevant cells.[1][6]
Pipeline Focus: Lead assets in Phase 1 (RCT1100 for PCD, RCT2100 for CF) with preclinical expansions (e.g., RTX0001, RCT-223 for CF; Dual SORT for A1AT deficiency), emphasizing disease-modifying therapies.[3][4]

These features position ReCode ahead of competitors reliant on liver-limited systems.[2]

Role in the Broader Tech Landscape

ReCode rides the mRNA and gene editing wave post-COVID vaccines, addressing a critical bottleneck: extra-hepatic delivery for rare diseases affecting lungs and beyond, where ~90% of genetic diseases originate outside the liver.[1][3] Timing aligns with maturing CRISPR/gene correction tools and LNP optimizations, amplified by market forces like orphan drug incentives, rising rare disease funding, and inhalation tech advances for pulmonary conditions like CF/PCD.[2][4] It influences the ecosystem by open-sourcing SORT principles via Siegwart's research, accelerating industry-wide adoption of targeted LNPs, while its preclinical-to-Phase 2 progress validates platform scalability for common diseases (e.g., CNS, infectious).[3][5][6]

Quick Take & Future Outlook

ReCode's near-term catalysts include Phase 2 data from RCT2100 in CF (initiated Nov 2025) and RCT1100 readouts in PCD, potentially de-risking SORT for partnerships or approvals in underserved indications.[4][5] Expanding to musculoskeletal/CNS via versatile administration will shape its path amid trends like combo therapies (e.g., with modulators like ivacaftor) and AI-optimized cargos.[3][6] Influence may evolve from rare disease pioneer to broad genetic medicine leader, powering accessible, redosable treatments—if delivery precision scales industrially—ultimately fulfilling its vision of transcending LNP limits for genetically defined diseases.[1][2]

Sources

Frequently Asked Questions

How much funding has ReCode Therapeutics raised?

ReCode Therapeutics has raised $210.0M in total across 3 funding rounds.

Who are ReCode Therapeutics's investors?

ReCode Therapeutics's investors include Bioluminescence Ventures, InterWest, Intuitive Ventures, MPM Capital, OrbiMed, Pfizer Venture Investments, Polaris Partners, Vida Ventures, Sam Altman.